Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Searle_Pharmaceuticals
|
| gptkbp:activities |
dopamine D2 receptor antagonist
serotonin 5-H T2 A receptor antagonist |
| gptkbp:approves |
gptkb:1993
gptkb:FDA |
| gptkbp:associated_with |
metabolic syndrome
cardiovascular events sedation cognitive impairment |
| gptkbp:brand |
gptkb:Risperdal_Consta
gptkb:Risperdal_M-TAB |
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
hypersensitivity to risperidone
severe CNS depression |
| gptkbp:developed_by |
gptkb:Johnson_&_Johnson
|
| gptkbp:dosage_form |
2-6 mg/day
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Risperidone
|
| gptkbp:ingredients |
C23 H27 Cl N4 O2
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P2 D6 inhibitors |
| gptkbp:is_atype_of |
N05 A X08
|
| gptkbp:is_available_in |
generic form
|
| gptkbp:is_available_on |
gptkb:tablet
oral solution orally disintegrating tablet long-acting injection |
| gptkbp:is_used_for |
schizophrenia
bipolar disorder irritability associated with autism |
| gptkbp:lifespan |
20 hours
|
| gptkbp:manager |
oral
intramuscular |
| gptkbp:marketed_as |
gptkb:Risperdal
|
| gptkbp:metabolism |
liver
|
| gptkbp:requires |
available online
|
| gptkbp:side_effect |
drowsiness
constipation dry mouth weight gain hyperlipidemia hyperglycemia extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia prolactin elevation |
| gptkbp:type_of |
106266-06-2
|
| gptkbp:used_in |
pediatric patients
adult patients geriatric patients acute mania treatment-resistant schizophrenia |